# Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)

> **NCT01788332** · PHASE2 · UNKNOWN · sponsor: **Lisette Nixon** · enrollment: 70 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Olaparib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01788332
- **Lead sponsor:** Lisette Nixon
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01788332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01788332, "Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01788332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*